management of cough in lung cancer
DESCRIPTION
Management of cough in lung cancer. Clinical guidelines for the management of cough in lung cancer: report of a UK Task Group on Cough. Molassiotis A 1 , Smith JA 2 , Bennett MI 3 , Blackhall F 4 , Taylor D 5 , Zavery B 6 , Harle A 4 , Booton R 7 , - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/1.jpg)
Management of cough in lung cancer
![Page 2: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/2.jpg)
Clinical guidelines for the management of cough in lung cancer:
report of a UK Task Group on Cough.
Molassiotis A1, Smith JA2, Bennett MI3, Blackhall F4, Taylor D5, Zavery B6, Harle A4, Booton R7,
Rankin EM8, Lloyd-Williams M9, Morice AH10.
![Page 3: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/3.jpg)
Epidemiology
• Cough is common symptom– 23-37% of all cancer patients– 47-86% in lung cancer
• Not always well managed
• Little evidence to guide practice
![Page 4: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/4.jpg)
• Formation of task group
• Literature reviews
• Peer review by UK committees
• Submitted for publication
![Page 5: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/5.jpg)
Pathophysiology
• Coughing serves to protect airway from irritants
• Stimuli provoke cough via vagus nerve through– chemoreceptors (C fibres)– mechanoreceptors (A delta fibres)
![Page 6: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/6.jpg)
In lung cancer• Ulceration of mucosa
– Mechanical stimulation
• Release of inflammatory mediators– Chemoreceptor stimulation– Sensitises peripheral nerves
• Also:– Obstruction– Pleural effusion– Infection– Fistulas– Carcinomatosis
![Page 7: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/7.jpg)
Recommendations
![Page 8: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/8.jpg)
Assessment• History– Type of cough (productive / non-productive)– Trigger factors– Nocturnal or day time
• Co-morbid conditions– COPD– Heat failure
• No validated symptom scale available
![Page 9: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/9.jpg)
Assessment
• Drugs causing cough– Methotrexate– Bleomycin– ACE inhibitors
• Further investigations– ?CXR– CT
![Page 10: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/10.jpg)
Treat reversible causes
• COPD / asthma– Inhaled bronchodilators– Steroid (prednisolone 30mg daily)
• Infection (bronchietctasis, LRTI)– antibiotics
• GI reflux– PPI (omeprazole)– Metoclopramide or domperidone for non-acid reflux-
![Page 11: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/11.jpg)
Treat the cancer
• Chemo– Improves symptoms including cough
• External radiotherapy
• Brachytherapy
![Page 12: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/12.jpg)
Symptomatic management
• Linctus– Glycerol– Simple linctus
• Trial of steroid– Prednisolone– (or dexamethasone)
![Page 13: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/13.jpg)
Centrally acting agents
• Codeine– 30mg qds
• Morphine or methadone– If codeine no help– Morphine 5-10mg bd• No dose response relationship for cough
![Page 14: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/14.jpg)
Peripherally acting agents
• Antitussive agents– Levodropropizine,– Moguisteine – Levocloperastine
• Local anaesthetic agents– nebulised bupivacaine– benzonatate
![Page 15: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/15.jpg)
In general
• Low levels of evidence for these recommendations
• Peripheral and intermittent approaches before central and continuous treatment
• In lung cancer– many patients already on opioids for pain• Central approaches maximised already
![Page 16: Management of cough in lung cancer](https://reader035.vdocuments.us/reader035/viewer/2022062517/56813244550346895d98b437/html5/thumbnails/16.jpg)
LOCAL ANAESTHETICSNebulised Lidocaine
Benzonatate
PERIPHERALLY-ACTING ANTITUSSIVESLevodropropizine, Moguisteine, Levocloperastine
OPIOIDSMorphine/Methadone
Dextromethorphan, Codeine, Hydrocodone
CANCER SPECIFICsystemic chemotherapy/RT endobronchial therapy, PDT, palliative RT
CO-MORBIDITIESCOPD, reflux, asthma, infections
CONSIDER ORAL STEROID TRIAL2 weeks
adjun
ctive
ther
apies
, anx
iety m
anag
emen
t and
voca
l hyg
iene t
echn
iques
EXPERIMENTALCarbamazepine,Thalidomide, Gabapentin, Baclofen Amitriptylline